News | Breast Imaging | January 08, 2016

Alpha Imaging to Distribute Gamma Medica’s Molecular Breast Imaging System

Large independent sales and service provider will bring LumaGEM system to the Midwest, Mid-Atlantic regions

Gamma Medica, Alpha Imaging, LumaGEM molecular breast imaging system, MBI, distribution agreement

January 8, 2016 — Alpha Imaging, an independent sales and service provider of advanced medical imaging equipment, announced that it has executed a distribution agreement with Gamma Medica Inc. The agreement covers distribution of Gamma Medica's LumaGEM molecular breast imaging (MBI) solution in the Midwest and Mid-Atlantic regions.

MBI is a new technology that greatly improves detection of early cancers in women with dense breast tissue and complex mammograms, addressing the shortcomings of mammography and other screening modalities.

Recently published studies have shown the addition of MBI for women with dense breast tissue results in a four-times increase in invasive breast cancer detection rates as part of a secondary screening protocol. Use of MBI also showed a 50 percent reduction in biopsies and a subsequent 15 percent lower cost per cancer detected than screening with mammography alone.

Dense breast tissue makes it more difficult to detect cancer, since both lesions and dense tissue appear white on a mammogram. According to recent publications, MBI is a functional imaging modality that highlights metabolic activity in breast tumors not visible on mammography due to tissue density, thereby leading to earlier diagnosis, improved outcomes and lowered costs.

It is important for women to discuss with their doctors if MBI is an appropriate screening method for them. In addition to women with dense breast tissue or suspicious lesions, MBI may also be valuable for high-risk patients with a family history of breast cancer, patients who have tested positive for BRCA1 or BRCA2 genes, symptomatic patients, patients with cosmetic augmentation or patients who cannot receive a magnetic resonance imaging (MRI) exam.

For more information: www.gammamedica.com

Related Content

Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
Barco Highlights Imaging Workflow Compliance at HIMSS18
News | Flat Panel Displays | February 21, 2018
Barco will showcase its full line of radiology and mammography display systems with online quality assurance (QA)...
DenseBreast-info.org Launches European-Focused Education Coalition
News | Breast Density | February 19, 2018
DenseBreast-info.org (DB-I) announced plans for international expansion with specialized content for Europe and...
Radiography Education Enrollment Shows Marginal Rise in 2017
News | Business | February 15, 2018
Directors of radiography educational programs report the number of enrolled students increased slightly in 2017, while...
AHRA and Canon Medical Systems Announce 2017 Putting Patients First Grant Winners
News | Patient Engagement | February 14, 2018
The Association for Medical Imaging Management (AHRA) and Canon Medical Systems recently announced the tenth annual...
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Microbubbles Make Breast Cancer More Susceptible to Radiation Therapy
News | Women's Health | February 01, 2018
February 1, 2018 – Injecting breast cancer with oxygen-filled microbubbles makes tumors three-times more sensitive to
Overlay Init